Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr 30;65(2):138-145.
doi: 10.3325/cmj.2024.65.138.

Factors contributing to variability in metformin concentration in polycystic ovary syndrome

Valentina N Nikolić #  1 , Milan Stefanović #, Dejan Mitić, Slavica Sunarić, Maša Jović, Hristina Trajković, Sanja Stanković, Aleksandra Ignjatović, Dragana Stokanović #
Affiliations

Factors contributing to variability in metformin concentration in polycystic ovary syndrome

Valentina N Nikolić et al. Croat Med J. .

Abstract

Aim: To investigate the factors affecting metformin concentrations after chronic administration in patients with polycystic ovary syndrome (PCOS), focusing on the pharmacokinetic variability and its implications for personalized therapy.

Methods: This study enrolled 53 PCOS patients undergoing long-term metformin treatment at the Clinic for Gynecology and Obstetrics in Niš, Serbia, from February to December 2019. Pharmacokinetic parameters were measured from blood samples, and metformin concentrations were determined with validated analytical techniques.

Results: There was a significant variability in metformin concentrations among PCOS patients, with body mass index (BMI) identified as a major influencing factor. Higher BMI was associated with lower plasma metformin levels, a finding suggesting an altered pharmacokinetic profile in obese patients.

Conclusions: This study highlights the critical role of BMI in influencing metformin pharmacokinetics in PCOS patients and underscores the need for personalized treatment strategies in patients with PCOS.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Correlation between corrected metformin concentration and body mass index (BMI).
See this image and copyright information in PMC

References

    1. Escobar-Morreale HF. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nat Rev Endocrinol. 2018;14:270–84. doi: 10.1038/nrendo.2018.24. - DOI - PubMed
    1. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19:41–7. doi: 10.1093/humrep/deh098. - DOI - PubMed
    1. Rudnicka E, Suchta K, Grymowicz M, Calik-Ksepka A, Smolarczyk K, Duszewska AM, et al. Chronic low grade inflammation in pathogenesis of PCOS. Int J Mol Sci. 2021;22:3789. doi: 10.3390/ijms22073789. - DOI - PMC - PubMed
    1. Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022;65:1925–66. doi: 10.1007/s00125-022-05787-2. - DOI - PMC - PubMed
    1. Kazerooni T, Dehghan-Kooshkghazi M. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome. Gynecol Endocrinol. 2003;17:51–6. doi: 10.1080/gye.17.1.51.56. - DOI - PubMed